INDGN/SE/2026-27/48

19 August 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Sub: Update on Material Litigation under the Telephone Consumer Protection Act, 1991 Involving Wholly-Owned Subsidiary, Indegene, Inc.

We wish to inform you that Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and in continuation of disclosures previously made by Indegene Limited ("the Company") in its initial public offer documents and subsequent financial results, the Company is providing an update on material development in relation to the ongoing class-action lawsuit pending against our wholly-owned overseas subsidiary, Indegene, Inc., before the U.S. District Court, District of New Jersey.

The lawsuit (Progressive Health and Rehab Corp. v. Indegene, Inc. et al.) relates to alleged violations of the U.S. Telephone Consumer Protection Act, 1991 (TCPA) concerning certain fax communications executed in February 2020. Following certification of the class in July 2025 and denial of the defendants' petition seeking permission to appeal the class certification, the parties participated in court-referred mediation and thereafter negotiated the settlement terms and definitive settlement documentation.

The parties have now substantially concluded negotiations on the definitive settlement agreement. Following final clarifications from external counsel on August 18, 2026, the Company has confirmed that it has no further comments on the settlement agreement and has authorized the same to proceed for execution. The settlement remains subject to execution by the relevant parties and approval of the U.S. District Court. The settlement does not constitute an admission of liability by the Company or the defendants.

The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are annexed to this letter.

The above information is being made available on the website of the Company https://www.indegene.com/

Kindly take the above-said information on record.

For Indegene Limited

SRISHTI RAMESH KAUSHIK

Digitally signed by SRISHTI RAMESH KAUSHIK
Date: 2026.08.19 10:56:16 +05'30'

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer
Encl: A/a

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
compliance.officer@indegene.com
www.indegene.com

CIN: L73100KA1998PLC102040

Annexure – I

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sl. No	Particulars	Details
1.	Name of Opposing Party	Progressive Health and Rehab Corp., individually and on behalf of a certified class.
2.	Court / Agency where litigation is filed	U.S. District Court, District of New Jersey.
3.	Brief Details of Dispute / Litigation	Class action litigation alleging violations of the U.S. Telephone Consumer Protection Act, 1991 in connection with certain alleged unsolicited fax communications. In July 2025, the Court certified a class comprising approximately 18,851 unique fax numbers (18,869 transmissions). The defendants' petition seeking permission to appeal the class certification was subsequently denied. The matter thereafter proceeded through mediation and settlement negotiations.
4.	Expected financial implications, if any, due to compensation, penalty etc.	The settlement framework provides for a maximum settlement fund of approximately USD 4.72 million, calculated at USD 250 per eligible fax/claim under the agreed framework. The settlement is structured on a claims-made and reversionary basis, under which the actual amount payable to class members will depend upon the number of valid and approved claims submitted. Amounts not required to satisfy approved claims and other payments contemplated under the settlement will remain with/revert to the defendants in accordance with the settlement terms. The defendants are not required to deposit or pre-fund the entire USD 4.72 million settlement fund, and payments will become due in accordance with the settlement agreement and Court-approved process. The Company has assessed/shall assess the accounting impact in accordance with applicable accounting standards.
5.	Quantum of Claims, If any	The certified class comprises approximately 18,851 unique fax numbers relating to 18,869 transmissions. The agreed settlement framework provides for USD 250 per eligible approved claim, subject to the terms and conditions of the definitive settlement agreement. The resulting maximum settlement fund is approximately USD 4.72 million; however, this represents the contractual maximum and not the expected cash outflow, since the settlement is claims-made and actual payments will depend on valid claims received and approved.

6	**The details of any change in the status and/or any development in relation to such proceedings**	Since the Company's previous disclosure, the settlement has progressed from mediation and negotiation of settlement documentation to finalization of the definitive settlement agreement from the Company's perspective. External counsel circulated the finalized settlement agreement for execution and, following resolution/clarification of the remaining points, the Company confirmed that it has no further comments and authorized the agreement to proceed for signature. The agreed notice mechanics contemplate an initial fax notice and, where unsuccessful, notice by U.S. First Class Mail. The parties have identified Analytics as settlement administrator at an estimated administration cost of approximately USD 42,559. The settlement does not require upfront funding or escrow of the maximum settlement fund. The next steps are execution by the relevant parties, filing of the settlement documentation with the Court, preliminary approval, class notice and claims administration, followed by final Court approval.
7.	**In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and/or any development in relation to such proceedings**	Not Applicable. The litigation is against Indegene, Inc. and certain subsidiaries and does not relate to litigation against the Company's key managerial personnel or ultimate person in control.
8.	**In the event of settlement of the proceedings, details of such settlement including terms of the settlement, compensation / penalty paid (if any) and impact of such settlement on the financial position of the listed entity**	The settlement framework provides for: (i) a maximum settlement fund of approximately USD 4.72 million; (ii) payment of USD 250 per eligible approved claim; (iii) a claims-made structure under which actual payments depend upon valid claims received and approved; (iv) retention/reversion to the defendants of amounts not required to satisfy approved claims and other agreed settlement payments; (v) no requirement to deposit, escrow or pre-fund the entire maximum settlement fund; (vi) payment of Court-approved class counsel fees and other amounts contemplated under the settlement agreement; and (vii) Settlement administration in accordance with the Court-approved notice and claims process. No payment has been made to class members at this stage. The definitive settlement remains subject to execution by the relevant parties and Court approval. Accordingly, the maximum settlement fund should not be interpreted as the expected cash outflow. The actual

		financial impact will depend principally on the number of valid claims ultimately submitted and approved, together with Court-approved counsel fees, administration costs and other amounts payable under the settlement agreement.

Note: This disclosure is in continuation of the disclosures previously made by the Company, including disclosures contained in the DRHP/RHP and subsequent financial results/stock exchange filings. The present disclosure updates the stock exchanges regarding the material development in the settlement process, namely the substantial conclusion of negotiations on the definitive settlement agreement and the Company's authorization to proceed with execution. The settlement remains subject to execution by the relevant parties and approval by the U.S. District Court.